*Actual product packaging may differ from the image shown.
AOD 9604
AOD-9604 Injectable Peptide is a specialized fat-loss peptide derived from a modified fragment of human growth hormone. It works by signaling the body to increase fat breakdown (lipolysis) and reduce new fat storage, making it a focused option for stubborn fat and metabolic optimization. AOD-9604 may be a good choice for individuals seeking improved body composition and long-term weight management without systemic hormonal effects.
Protocols developed under the clinical direction of Dr. Jonathann Kuo, MD
Select Size:
What happens after checkout
- ①Purchase your treatment
- ②Complete your Qualiphy consultation via email (~3 min)
- ③Licensed provider reviews & approves your prescription
- ④Pharmacy ships within 3–5 days of approval
After checkout, you'll receive an email to complete your telehealth consultation. A licensed provider must approve before your order ships.
AOD-9604 is generally well-tolerated and often used as part of weight optimization and body composition protocols. Potential benefits may include:
- Promotes targeted fat loss by increasing lipolysis and reducing fat storage.
- Supports metabolic efficiency without stimulating growth hormone or IGF-1.
- Helps address stubborn or resistant fat areas.
- May support weight maintenance during or after weight-loss efforts.
- Complements nutrition, exercise, and other metabolic therapies.
- Pregnancy or Breastfeeding: Safety has not been established; use is not recommended.
- Active Cancer or Recent Cancer Treatment: Growth hormone–derived peptides are generally avoided.
- Known Allergy: Avoid use if you have a sensitivity to peptide-based therapies or formulation components.
- Severe Liver or Kidney Disease: Should be used only under medical supervision.
AOD-9604 is generally well tolerated, but mild, short-term effects may occasionally occur, especially when first starting, including:
- Temporary redness, tenderness, or itching at the injection site
- Mild headache or light fatigue
- Temporary changes in appetite or digestion as metabolism adjusts
These effects are typically mild and resolve as the body adapts.
For safe and informed use, review the Extension Health Injection Reaction Guide (PDF), which outlines what to expect, how to reduce discomfort, and when to seek medical support.
- Weeks 1–2: AOD-9604 begins signaling fat cells to increase fat breakdown (lipolysis) while reducing new fat storage. At this stage, changes are happening primarily at the cellular and metabolic level, and visible fat loss may be subtle. Some patients notice early shifts in appetite awareness, energy, or how their body responds to exercise.
- Weeks 3–6: As metabolic signaling becomes more consistent, the body becomes more efficient at using stored fat for fuel. Patients may begin to notice gradual changes in body composition, especially in stubborn or resistant fat areas, when AOD-9604 is paired with nutrition and movement.
- Weeks 8–12: Sustained use supports ongoing fat utilization and metabolic efficiency. Visible improvements in body composition, weight stability, and fat distribution are more likely during this phase. Results tend to be gradual and steady rather than rapid, making AOD-9604 well-suited for long-term weight management rather than short-term weight loss.